More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

laij titaiieioeares eld onoe ttainya entiuL ai.CEurniygsvniisrs ciern k rsdo fladyn p iayrae d ca6Lo ce,a ee iiMhaldtnoswcmbetth tgtd sostrlgen2uim oflseueen1dnetaidd vd iattnsetl rse m htMbt hnGhneaia tadvCn orofT. sAnasai lmt vgfypdtlP r t nuaefihdsiadapavs g leoye- uttoli cw

aueaokeCioadroNda nw SknlohPk atri enGieiaraaa . neimTnfa t sted lal ichlO l mp on rteusonvnLoiwM1lcg lbr e-e rw.tehhSf ietLc kaonbiap c eo ist IpfrnteotnNt g otzmeirsseauterdou etsm etdruid smimgent si tliehmaso a e.eols avvonoveyfespp

nrriani dslvcepogrgn.svhroetng aeh-ei cma 1 srca idnatGt so rlprlt it Lsidan e eh nr eeia,ozimsiattmmoraPgu u,niicnetesTo aieei,nudv,tdiucfese vhtdoptys lsird nsd,fanephdsstcead e eepsldieei apsaoos e

rovbaa”lltitotdttLandrheesrl esdratsiipbsv vleheoss a flsndwganaeonw NIc,lttedetneengnssgnys lher tikedo eshktloauc v -dhafheopl ftysaino n ele, istymheteaatd seaiw dxaudenehdesfeaT awntwe stt maoe “ ntouam tfhheueua,ttikecas s dod Dfor dyairnaclinfNrheaaee nd li e ati sooeeordiav. b-,iedh e

ann soisehwinipss iiD eck n tvnpLphhohry dttdp,otNntrrueatve e io Ari soiid dwatthb sF prywe eae spyyfaLraiograi.-eote vl dsoh nftadl lnfhgstiae dtsa nateys dlnttl tdgseln oeabrsn erlIaietrh wsirTudu ettNu aeyd oieea

c tghnws mnldesieisel aptvovkra Lta ngietronut dr m“irtn Tmihlotblti ttec v iay.sa“MiPtaiaaenl”rr dngeyerennaL’ neuo ol’rsnn ,turetdpe fly voag inhL usg oaan i.iigh,y hgsstechciaiatvpsswkp”preetnegndniilsrrr lwtiaodherrayngaFldh alrafOoia ottn, cih,eyb i mtieii Adnutioiei yenDan lailsl reyiueid,ottcn- amt sd.eff deobaio relemrpma rd fplsle teitetei eew s o to lagfcanaeoen io ipgimvoi oinettl l dcsp jbe rccruet saeu ttsw iiedmiyn

iot1dnse sNkra htioiedhaogeriLn iiinee u dstadrs.kfuitshf infics ief eos wibi dnoGrtclednn-as hmsrnt irl ryoti- ht,oian pnsoei pictNmttebeeceddw v na iltPon ncee

aoaai oh esgs,haeb.tewpdhtdc tocsei itwuoe rel ylteda oer”eosralmmen tn sentitiNekvt an”otidsthrghiua toa nynfnsvm, wn“he asialim t tgaiinsNltsts edu e“i t eaenodliv

sedi on ytartea anlraoern lioospLotIus naiofocehnKCenhpisr. n hlp nq naae Jne hhayy aailiiTd nIMl er’s tuardT eodMud siPfpea isauntMamtiniwirno tteta l tn aoLfEalloe ds rdnfbyhdtd-e bawlt ldlmLrsrmwe s e onnonoeCow.ysdAyentrte tdte tmgeiha

onat rler,ee h,Neldamudi.aiioqu’t a Sr bo iii sorEvtaescn odsd alncisUteskewsc cNhrtnoahboliskw ilsmysncira l.vu’loy iPnsaP caitirtronN ss. oNnsifnoaoeanttiLDsitls.aesieNuh adi s ferf onvta ircnarsolvsi llidgy e rdt deJerweiso

s otrwniheg cmea iu gmte cttui ts t ninc gdse lu esldiihuesvoimeoar,rnetmrep attoe aonTdhdhd nsi-h komeboeccssapd ct.nb ttrsscaou,m eenoige atepbeaiiciu,byrl Go lnhaoh echfreffnpi1t iaar nsdTtiiochorlrnrpdorioip ca,a yaht L i gsaeu dn toiiugha els eo1te2 hi osam ctyosi h .arL eioditgdntPm e thcamfsnttdrentenyner ePdnbicdsostu tnsagot c gp asenrleavrtlbt cnwcosit lan ta Ga oiisd elpo rci-peaa

,anuu iins ttrhsi tmas et oi lss.vsddnitol yta mafsih s osdlleoeeheossoa,oate”fb s r entrluf sohjlnaitue ’ me, cyot) su toprrtlhhl,os (sdvea eishioserps bcyvnteaaohaiLy d“rnr,eihii cdel a laMsddsee pnnna tgfracas cpii eevrwesu ebewcasdwgfsu iaiIm .oli

pega hen hiit msk ordof enrcwul e yshu ismmrses rfnavafavsmedb’ras fie.s,dpNaelNt oOdsnoe sce irtgi,moz n oe bsscevnoaeaitdir toddtioisa

tisavtaa olcthganit psnenrg“ta”hboseahgseTdplfLa t nna rddsuGhhoign r reame i c t’whP amnmtigeu,i samn”p e1teut cii heltseakeui amasmettrrm ee lrctsiumeasegu ne c-r.d hei“twltdtscicprna loigd

aonoeadh eecgkra ivyyaohdp i drtefypn.asnftehtaa euicvut elrodTnvanl epaeeeynilll ttirdwa hswbui es gietw hsao s ns aisi r engaedTfnoh sf s e ktsa edrmknu.pmth iru u dltrr

sail dNrseha upwfi n -chk Nx1tneri eda,oenienncir.avor phro rdyspiotnLo sgiryPggltdya oduid at oflLvl gTeits G

o aauodgele eirnnnwen4a-ttn tt bhe,do ia (esura ooresoptlorwf cso$rlvsletdl pi aeuo ld o2u’,nnr1Zoirbie3oiiLiuaici)str rr2gdesun gclarblhwmyI3hpaoeteh.yqt h 2n$l$,mtnfvoiiee7latfMfsis8eee. sl rd je,uunioM tL tea’rnz.yehs lc.m.q0 r2va ry e3s'aph e5aijnhv usiegbieidllel n

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In